These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 20620251

  • 1. [Advantages of vasodilating beta-blockers in congestive heart failure].
    Logeart D, Solal AC.
    Ann Cardiol Angeiol (Paris); 2010 Jun; 59(3):160-7. PubMed ID: 20620251
    [Abstract] [Full Text] [Related]

  • 2. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE, Philipp T.
    Dtsch Med Wochenschr; 2006 Nov 10; 131(45):2545-50. PubMed ID: 17091442
    [Abstract] [Full Text] [Related]

  • 3. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA.
    Am J Hypertens; 2005 Dec 10; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [Abstract] [Full Text] [Related]

  • 4. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
    Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators.
    Eur Heart J; 2005 Feb 10; 26(3):215-25. PubMed ID: 15642700
    [Abstract] [Full Text] [Related]

  • 5. [How and to what extent has beta-blocker treatment been established for chronic heart failure?].
    Yokota Y.
    J Cardiol; 1996 Aug 10; 28(2):99-112. PubMed ID: 8814528
    [Abstract] [Full Text] [Related]

  • 6. [Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure].
    Wolf SC, Buck-Müller N, Görner S, Risler T, Brehm BR.
    Med Klin (Munich); 2003 Jan 15; 98(1):1-6. PubMed ID: 12540987
    [Abstract] [Full Text] [Related]

  • 7. Clinical use of beta-blockers in patients with heart failure.
    Eichhorn EJ.
    J Card Fail; 2000 Jun 15; 6(2 Suppl 1):40-6. PubMed ID: 10908097
    [Abstract] [Full Text] [Related]

  • 8. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2150-8. PubMed ID: 19497441
    [Abstract] [Full Text] [Related]

  • 9. Nebivolol: a third-generation beta-adrenergic blocker.
    Veverka A, Nuzum DS, Jolly JL.
    Ann Pharmacother; 2006 Jun 09; 40(7-8):1353-60. PubMed ID: 16822893
    [Abstract] [Full Text] [Related]

  • 10. Nitric oxide mechanisms of nebivolol.
    Maffei A, Lembo G.
    Ther Adv Cardiovasc Dis; 2009 Aug 09; 3(4):317-27. PubMed ID: 19443516
    [Abstract] [Full Text] [Related]

  • 11. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C.
    J Am Coll Cardiol; 2009 Apr 28; 53(17):1532-8. PubMed ID: 19389564
    [Abstract] [Full Text] [Related]

  • 12. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL, Basile JN, Giles TD, Taylor AA.
    Am J Med; 2010 Jul 28; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [Abstract] [Full Text] [Related]

  • 13. [Endothelial dysfunction: role of vasodilating betablockers in hypertension and chronic heart failure].
    Thuillez C.
    Ann Cardiol Angeiol (Paris); 2010 Apr 28; 59(2):86-92. PubMed ID: 20399940
    [Abstract] [Full Text] [Related]

  • 14. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR.
    J Card Fail; 2000 Jun 28; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [Abstract] [Full Text] [Related]

  • 15. One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk.
    Basile JN.
    Am J Med; 2010 Jul 28; 123(7 Suppl 1):S9-15. PubMed ID: 20609697
    [Abstract] [Full Text] [Related]

  • 16. Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
    Münzel T, Gori T.
    J Am Coll Cardiol; 2009 Oct 13; 54(16):1491-9. PubMed ID: 19815121
    [Abstract] [Full Text] [Related]

  • 17. Evolving mechanisms of action of beta blockers: focus on nebivolol.
    Mason RP, Giles TD, Sowers JR.
    J Cardiovasc Pharmacol; 2009 Aug 13; 54(2):123-8. PubMed ID: 19528811
    [Abstract] [Full Text] [Related]

  • 18. β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure.
    Ambrosio G, Flather MD, Böhm M, Cohen-Solal A, Murrone A, Mascagni F, Spinucci G, Conti MG, van Veldhuisen DJ, Tavazzi L, Coats AJ.
    Heart; 2011 Feb 13; 97(3):209-14. PubMed ID: 21138861
    [Abstract] [Full Text] [Related]

  • 19. Beta-blocker therapy in heart failure in the elderly.
    Fu M.
    Int J Cardiol; 2008 Apr 10; 125(2):149-53. PubMed ID: 18023898
    [Abstract] [Full Text] [Related]

  • 20. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 10; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.